IRadimed Corporation — FY2014 Form 10-K
Reporting period: Fiscal year ended December 31, 2014. Although the request references 2014 Q4, this filing is an annual report; the supplied text does not provide a clear standalone fourth-quarter income statement or cash flow.
Business context
IRadimed develops and sells MRI-compatible medical devices, principally its MRidium non-magnetic IV infusion pump system. Revenue comes from pump and accessory sales, disposable IV tubing sets, and services. At year-end, the company estimated approximately 2,300 installed pump systems worldwide; U.S. sales were direct and international sales were through distributors.
Financial results and liquidity
| Metric | FY2014 | FY2013 |
|---|---|---|
| Revenue | $15.65 million | $11.34 million |
| Gross profit / gross margin | $12.25 million / 78.3% | $8.49 million / 74.8% |
| Operating income / margin | $3.07 million / 19.6% | $2.79 million / 24.6% |
| Net income / net margin | $2.05 million / 13.1% | $1.94 million / 17.1% |
| Diluted earnings per share | $0.20 | $0.22 |
| Cash provided by operating activities | $2.59 million | $1.47 million |
- Revenue rose 38%, driven by more pump systems sold and higher disposable-set sales. Device revenue was $12.81 million; disposable IV sets and services contributed $2.84 million. The company sold 536 pumps versus 424 in 2013; average system selling price increased to approximately $23,800 from $22,000.
- Gross margin improved, which management attributed primarily to favorable materials variances. Operating margin declined as operating expenses grew faster than revenue, notably general and administrative expense, which more than doubled to $4.82 million.
- U.S. revenue was $11.36 million (72.6% of total); international revenue was $4.30 million (27.4%).
- At December 31, 2014, cash and cash equivalents were $9.45 million and investments were $7.91 million; working capital was $19.9 million and stockholders’ equity was $20.89 million. Total assets were $23.31 million and total liabilities $2.42 million. No material borrowings were reported at year-end; the CEO’s interest-free note was repaid in March 2014, and the $100,000 revolving credit facility was terminated.
- Investing activities used $8.30 million, principally for purchases of corporate debt securities; financing activities provided $12.71 million, primarily from the IPO. IPO net proceeds were approximately $12.4 million. The filing reports no off-balance-sheet arrangements.
Material changes and unusual items
- The FDA issued a Warning Letter on September 2, 2014, alleging that software modifications to the MRidium 3850 and 3860 required new 510(k) submissions and requesting that U.S. distribution cease. IRadimed stopped U.S. sales and distribution, submitted a 510(k) for the 3860+, and resumed U.S. distribution of that system without DERS on December 22, 2014, under FDA enforcement discretion. DERS distribution resumed in January 2015, after year-end. The FDA review and Warning Letter remained unresolved in the filing.
- Management said the distribution stoppage significantly affected 2014 results and expected above-normal expenses until FDA matters were resolved. The filing does not quantify the revenue or profit impact separately.
- The company completed its IPO in July 2014, raising approximately $12.4 million net, and its shares began trading on Nasdaq. Diluted EPS decreased despite higher net income, reflecting a larger weighted-average share count.
- Two international customers represented approximately 35% of gross accounts receivable at year-end, compared with one customer at approximately 11% in 2013. A single international customer’s 2013 pump order represented approximately 11% of that year’s revenue.
Outlook, risks and contingencies
- Management expected 2015 revenue to increase, citing sales-force expansion, market education, conversion of customers using Bayer’s Continuum pumps, and broader hospital adoption. No numerical revenue or earnings guidance was provided.
- Management expected 2015 operating expenses to increase due to headcount, the new headquarters, FDA remediation, legal costs, depreciation and public-company costs. It stated that available liquidity should fund projected needs for at least 12 months.
- Key risks include dependence on the MRidium pump and related consumables; continuing FDA review and possible further restrictions; product quality, recalls and regulatory compliance; and reliance on a sole-source ultrasonic motor and other limited-source components.
- A securities class-action lawsuit filed in September 2014 alleged failures to disclose material FDA-compliance information. The company disputed the allegations, intended to defend the case, and recorded no loss because it considered a loss not probable or estimable. A German trademark dispute was settled in March 2015 for the amount accrued; the company may continue using the iRadimed name in the EU.
- Additional exposures include customer and distributor concentration, foreign-exchange and investment fair-value risk, a related-party lease with the CEO’s affiliate, and the 2.3% medical-device excise tax. The company reported an approximately $140,000 estimated fair-value sensitivity to a 100-basis-point interest-rate change in its investments.
Important facts for investors to verify
- Current status and terms of FDA clearance, the Warning Letter, and any remaining restrictions on U.S. sales or DERS.
- Subsequent revenue, margins, cash generation and expenses compared with management’s directional 2015 outlook.
- Progress in resolving the securities litigation and any related legal costs, claims or settlements.
- Customer receivable concentration and the collectability of balances owed by the two international customers.
- Continuity of key component supply, especially the sole-source motor, and progress toward alternate suppliers.
- Backlog was approximately $19.5 million at December 31, 2014, but orders could be cancelled or rescheduled and management cautioned it was not a reliable indicator of future sales.